` VPA1 (Aveo Pharmaceuticals Inc) vs DAX Index Comparison - Alpha Spread

VPA1
vs
DAX Index

Over the past 12 months, VPA1 has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's 30% growth.

Stocks Performance
VPA1 vs DAX Index

Loading
VPA1
DAX Index
Add Stock
www.alphaspread.com

Performance Gap
VPA1 vs DAX Index

Loading
VPA1
DAX Index
Difference
www.alphaspread.com

Performance By Year
VPA1 vs DAX Index

Loading
VPA1
DAX Index
Add Stock

Competitors Performance
Aveo Pharmaceuticals Inc vs Peers

DAX Index
VPA1
ABBV
AMGN
GILD
VRTX
Add Stock

Aveo Pharmaceuticals Inc
Glance View

Market Cap
476.7m EUR
Industry
Biotechnology

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2010-03-12. The firm is focused on delivering medicines for patients with cancer. The Company’s commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The firm markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. The company also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company’s pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).

VPA1 Intrinsic Value
Not Available
A
Back to Top